376
Participants
Start Date
May 9, 2020
Primary Completion Date
December 30, 2025
Study Completion Date
December 30, 2025
TJ004309
Antibody to CD73
Toripalimab
Humanized monoclonal antibody to PD-1
The First Bethune Hospital of Jilin University, Changchun
Fudan University Shanghai Cancer Center, Shanghai
Guangdong Provincial People's Hospital, Guangzhou
The First Affiliated Hospital of Anhui Medical University, Hefei
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing
Army Medical Center of PLA, Chongqing
Chongqing Cancer Hospital, Chongqing
Guangdong Provincial Hospital of Chinese Medicine, Guangzhou
Cancer Hospital affiliated to Shantou University Medical College, Shantou
The First Affiliated Hospital of Guangxi Medical University, Nanning
Harbin Medical University Cancer Hospital, Haerbin
Henan Cancer Hospital, Zhengzhou
Hubei Cancer Hospital, Wuhan
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Hunan Cancer Hospital, Changsha
Northern Jiangsu People's Hospital, Yangzhou
The Second Affiliated Hospital of Nanchang University, Nanchang
Liaoning Cancer Hospital and Institute, Shenyang
The First Hospital of China Medical University, Shenyang
The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an
Sichuan Cancer Hospital, Chengdu
Yunnan Cancer Hospital, Kunming
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hanzhou
TJ Biopharma Co., Ltd.
INDUSTRY